(Bloomberg) -- McKesson Corp. and the private equity firm Clayton Dubilier & Rice will buy Option Care Health Inc. for an enterprise value of about $5.8 billion, expanding into the medical infusion ***** e.
Most Read from Bloomberg
New Hazard for Treasuries Hides in Bond Futures' Fine Print
Manchester City Verdict Strains UK-UAE Diplomatic Relations
As Thailand Cracks Down on Foreigners, a Tourist Paradise Reconsiders Its Welcome

#care

Alluvium ******* et Management, an ******* et management company, released its "Conventum – Alluvium Global Fund" second-quarter 2026 investor letter. The letter can be downloaded here. The second quarter reflected a sharp shift from geopolitical uncertainty and oil market volatility to a powerful equity rally led by semiconductor companies. Despite the broader market strength, the Fund declined 1.4% in EUR terms, 2.2% in USD terms, and 3.9% in AUD terms. Portfolio results were mixed, with Alphabet benefiting from strong Cloud growth, while Robert Half, H&R Block, and other holdings posted solid gains. However, cable businesses and several healthcare and consumer holdings weighed on performance. Also, check the fund's top five holdings to see its best picks in 2026.
In its second-quarter 2026 investor letter, Conventum – Alluvium Global Fund highlighted McKesson Corporation (NYSE:MCK). McKesson Corporation (NYSE:MCK) is a leading healthcare services company headquartered in Irving, Texas. On September 15, 2026, McKesson Corporation (NYSE:MCK) closed at $899.56 per share. Over the past month. McKesson Corporation (NYSE:MCK) returned 5.37% and its shares gained 29.95% over the past 52 weeks. McKesson Corporation (NYSE:MCK) has a market capitalization of $106.21 billion, and its stock has traded with a range of $687.68 and $999.00.
Conventum – Alluvium Global Fund stated the following regarding McKesson Corporation (NYSE:MCK) in its Q2 2026 investor letter:
"Our two healthcare companies had a poor quarter (in terms of share price performance, not business fundamentals). McKesson Corporation (NYSE:MCK), the drug distributor (down 12.6%), reported its full year results which were perfectly in-line with our expectations. Management provided strong guidance for its next year's earnings, and reiterated its 13%-16% long term growth expectations. After feeding the numbers through our model, our valuation increased by 18%, and with the share price trading below it, we bought a little more such that it accounts for 6.8% of the Fund."
McKesson Corporation (NYSE:MCK) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 77 hedge fund portfolios held McKesson Corporation (NYSE:MCK) at the end of the second quarter which was 73 in the previous quarter. While we acknowledge the potential of McKesson Corporation (NYSE:MCK) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

#mckesson #alluvium #global

Alluvium ******* et Management, an ******* et management company, released its "Conventum – Alluvium Global Fund" second-quarter 2026 investor letter. The letter can be downloaded here. The second quarter reflected a sharp shift from geopolitical uncertainty and oil market volatility to a powerful equity rally led by semiconductor companies. Despite the broader market strength, the Fund declined 1.4% in EUR terms, 2.2% in USD terms, and 3.9% in AUD terms. Portfolio results were mixed, with Alphabet benefiting from strong Cloud growth, while Robert Half, H&R Block, and other holdings posted solid gains. However, cable businesses and several healthcare and consumer holdings weighed on performance. Also, check the fund's top five holdings to see its best picks in 2026.
In its second-quarter 2026 investor letter, Conventum – Alluvium Global Fund highlighted McKesson Corporation (NYSE:MCK). McKesson Corporation (NYSE:MCK) is a leading healthcare services company headquartered in Irving, Texas. On September 15, 2026, McKesson Corporation (NYSE:MCK) closed at $899.56 per share. Over the past month. McKesson Corporation (NYSE:MCK) returned 5.37% and its shares gained 29.95% over the past 52 weeks. McKesson Corporation (NYSE:MCK) has a market capitalization of $106.21 billion, and its stock has traded with a range of $687.68 and $999.00.
Conventum – Alluvium Global Fund stated the following regarding McKesson Corporation (NYSE:MCK) in its Q2 2026 investor letter:
"Our two healthcare companies had a poor quarter (in terms of share price performance, not business fundamentals). McKesson Corporation (NYSE:MCK), the drug distributor (down 12.6%), reported its full year results which were perfectly in-line with our expectations. Management provided strong guidance for its next year's earnings, and reiterated its 13%-16% long term growth expectations. After feeding the numbers through our model, our valuation increased by 18%, and with the share price trading below it, we bought a little more such that it accounts for 6.8% of the Fund."
McKesson Corporation (NYSE:MCK) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 77 hedge fund portfolios held McKesson Corporation (NYSE:MCK) at the end of the second quarter which was 73 in the previous quarter. While we acknowledge the potential of McKesson Corporation (NYSE:MCK) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

#NYSE #fund #conventum #global

Reuters reported that McKesson Corporation (NYSE:MCK) said it would buy privately held Precision Medicine Group in a deal valued at about $2.25 billion as part of a "years-long effort to strengthen its higher-growth businesses."
McKesson has been reshaping its portfolio by exiting non-core **** ets and streamlining its operations while investing in businesses such as oncology and specialty care. Precision Medicine Group, based in Bethesda, Maryland, provides clinical research, laboratory testing, and commercialization services that help biopharma companies develop and launch new medicines. It will become part of McKesson's Oncology & Multispecialty segment once the deal closes, though McKesson gave no completion timeline. CEO Brian Tyler said the acquisition would "enhance our clinical research and commercialization services, strengthen clinical trial execution, and broaden our clinical service offerings."
The deal fits neatly into a growth strategy McKesson Corporation (NYSE:MCK) has already been executing, not a scattershot bet. The company has spent recent years exiting non-core **** ets while specifically building out oncology and specialty care. It means this acquisition extends a strategy management has already proven willing to follow through on.
McKesson is adding Precision Medicine to its strongest-performing division rather than using the acquisition to revive a struggling business. Revenue in the Oncology & Multispecialty segment jumped 33% to $14.2 billion in the first quarter of fiscal 2026, while JP Morgan **** yst Lisa Gill said the acquisition will likely strengthen McKesson's biopharma offerings.
The purchase reflects disciplined capital recycling, not new debt-fueled expansion. McKesson said in April it would sell a minority stake in its medical-surgical solutions business to Apollo Funds for $1.25 billion while pursuing an IPO for that unit, showing the company is actively shedding slower-growth **** ets to help fund investments like this one.

#medicine #acquisition #deal

On the September 2 episode of Mad Money, Jim Cramer called Cardinal Health, Inc. (NYSE:CAH) one of his "absolute favorites" and mentioned its growing exposure to specialty pharmaceuticals and higher-margin healthcare services.
Cardinal's been running circles around McKesson and Cencora. They consistently put up the best numbers because this company has gradually become less of a commoditized service provider and more of a specialized player.
Cardinal Health, Inc.'s (NYSE:CAH) fiscal fourth-quarter revenue rose 6% to $63.7 billion but missed estimates, while adjusted earnings per share came in at $2.91. Excluding a $0.31 per share tariff refund benefit, adjusted EPS was $2.60. Management forecast fiscal 2027 non-GAAP EPS of $12.40 to $12.60, a 13% to 15% growth, while adjusted free cash flow is expected at $3.5 billion to $4 billion.
The revenue miss is less significant if the company continues converting pharmaceutical volume into earnings. Lower branded-drug prices, including those affected by Medicare negotiations, can reduce reported sales without a proportional decline in distributor fees. The shift toward generics can have a similar effect because lower-priced drugs generate less revenue but can support attractive margins and high volumes. As Cramer said:
Remember, volume is where Cardinal really makes the money, volume, okay? That's why I keep shrugging off the revenue misses.

#cardinal #less #billion #NYSE

Irving, Texas-based McKesson Corporation (MCK) distributes pharmaceuticals, medical-surgical supplies, and health and beauty care products. With a market cap of $100.1 billion, the company also develops, implements, and supports software that facilitates the integration of data throughout the health enterprise. In addition, McKesson offers **** ytic, care management, and patient solutions for payers.
Shares of this healthcare giant have outperformed the broader market over the past year. MCK has gained 25.5% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 20.5%. However, in 2026, MCK stock is up 5.5%, compared to the SPX's 12.1% rise on a YTD basis.
Soros Fund Management Opened a New Position in Nebius During Q2. What This Means for NBIS Stock.
Nvidia Earnings, Jackson Hole and Other Key Things to Watch this Week
Ahead of Nvidia Earnings, Here's What Barchart Data Says Comes Next for NVDA Stock

#data #Health #care #broader

The latest Consumer Price Index showed prices 3.4% higher in July than a year ago, well above the Federal Reserve's 2% target. Energy prices jumped 14.7%, electricity rose 4.2%, and food increased 3%. Producer prices, meanwhile, remained 4.7% higher than a year ago.
The Congressional Budget Office has specifically concluded that the Trump administration's policies have contributed to current inflationary pressure. Indeed, changes to trade, tax, spending, and immigration policy have all affected prices, demand, and labor supply. But this isn't about why inflation is getting worse. It's about how to position your portfolio to actually benefit from "Trumpflation."
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
There are several ways to build and protect your wealth during inflationary times: bonds, gold, and energy stocks. Here, I want to share with you two specific stocks that are actually positioned to benefit if prices continue to rise: pharmaceutical distributors McKesson (NYSE: MCK) and Cencora (NYSE: COR).
McKesson isn't a pharmaceutical manufacturer. It's responsible for moving enormous quantities of drugs from manufacturers to pharmacies, hospitals, and healthcare providers.

#prices #flashing

AbbVie (NYSE:ABBV) just moved a step closer to expanding one of its most recognizable brands. On August 4, the FDA accepted for review a supplemental Biologics License Application for Botox Cosmetic to treat masseter muscle prominence, the jaw-muscle bulge that can give a face a wider, squarer look. If cleared, Botox Cosmetic would become the first and only neurotoxin approved for that use in the US and the fifth aesthetic indication for a drug that already anchors AbbVie's fastest-growing units.
The filing rests on two Phase 3 studies, M21-416 and M21-417, both of which hit their main goal and showed statistically significant improvement in masseter prominence against a placebo, with p-values of 0.0046 and 0.0014. Twice as many treated patients called themselves satisfied compared with the placebo group, and the safety data lined up with Botox's long track record, with no new red flags. That is the AbbVie playbook in miniature: squeeze another approved use out of a drug it already owns rather than starting from zero.
The broader business backs that pattern up. In the quarter ended June 30, net revenue came in just under $17 billion, up more than 10% year over year, with immunology sales climbing 15% on Skyrizi and Rinvoq and neuroscience revenue jumping more than 20%. Management raised its full-year outlook for the second time this year, and the Humira patent-cliff drag that weighed on results for two years now looks largely behind the company.
Most of AbbVie's US product sales still flow through just three wholesale distributors, McKesson, Cardinal Health, and Cencora, a concentration that leaves the company exposed if any one relationship sours. The balance sheet carries real leverage too: a debt-to-equity ratio of roughly -21.1x as of its December 2025 filing means liabilities outweigh shareholder equity outright, and a current ratio near 0.7x offers less short-term cushion than many healthcare peers hold.
Patent protection for Skyrizi and Rinvoq remains a multi-year risk, and the Inflation Reduction Act already allows government price negotiation on products including Imbruvica and, notably, Botox itself. The pending $10.9 billion Apogee Therapeutics acquisition adds fresh debt and integration risk on top of that. Oncology revenue slipped almost 2% in the latest quarter, and the stock's 8% gain this year has trailed the S&P 500's 13%, with a trailing P/E near 70 that mostly reflects acquisition-related charges rather than the underlying business.

#revenue

McKesson Corporation (NYSE:MCK) is one of billionaire Cliff Asness' top 10 healthcare stock picks. On June 23, McKesson Corporation (NYSE:MCK) issued a recap of its annual McKesson ideaShare 2026 event and stated that it spotlighted AI-powered solutions for independent pharmacies. The conference was held between June 18 and June 21 at the Colorado Convention Center in Denver, and it brought together nearly 5,000 independent community pharmacy professionals from across the US.
Source: Unsplash
McKesson noted that the event centered on helping independent pharmacies navigate a rapidly shifting healthcare landscape. It added that major themes were the integration of artificial intelligence into pharmacy operations, the expansion of patient care services beyond traditional prescription dispensing, and the growing importance of community-based care as a driver of better health outcomes.
For the first time at ideaShare, McKesson hosted a Product Showcase where attendees could evaluate new tools and vote on the solutions they believed would have the greatest impact on their businesses and patients. The company noted that this shift gave pharmacy owners a more direct role in shaping the products and services offered to them.
Meanwhile, on June 2, McKesson closed a strategic investment deal with funds managed by affiliates of Apollo, in which Apollo acquired a minority stake in McKesson's Medical-Surgical Solutions (MMS) business. The transaction had been announced about six weeks earlier, on April 20.